Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(22):1636-1637; doi:10.1093/jnci/dji419
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Travis, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Travis, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

Bernard Fisher Reflects on a Half-Century's Worth of Breast Cancer Research

Kate Travis

The first 150 words of the full text of this article appear below.

Bernard Fisher, M.D., past chairman and scientific director of the National Surgical Adjuvant Breast and Bowel Project (NSABP), is widely credited with bringing clinical trials and statistical methodology to breast cancer research. Those efforts led to the elimination of the Halsted radical mastectomy, a severely disfiguring procedure that had been the standard breast cancer treatment for decades.


Figure Removed (Available Only in the Full Text)
View larger version (164K):
[in this window]
[in a new window]
  		Bernard Fisher, M.D., is widely credited as the driving force that brought clinical trials and statistical methodology to breast cancer research.

 
Fisher's involvement in breast cancer research began with a telephone call in the fall of 1957 from I. S. Ravdin, M.D., Fisher's mentor at the University of Pennsylvania. Ravdin had recently been appointed chairman of the Clinical Studies Panel of the Cancer Chemotherapy National Service Center at the National Institutes of Health. In the spring of 1957, he invited Fisher and 22 other surgeons to meet at Stone House on the . . . [Full Text of this Article]

What was the standard treatment for breast cancer when the first clinical trials began?

Why did you challenge the idea that more expansive surgery was better than less extensive surgery?

What led you to realize that a randomized clinical trial was needed to test that hypothesis?

Was there resistance to the lumpectomy trial?

Did many of the clinical trials you conducted originate from biological hypotheses?

How did the Breast Cancer Prevention Trial get started, and was there any resistance to the study?

What message has resulted from the P-1 update?

Has evidence-based medicine created a paradox?

What are the misperceptions about clinical trials?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
A. Kendall and M. Dowsett
Novel concepts for the chemoprevention of breast cancer through aromatase inhibition.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 827 - 837.
[Abstract] [Full Text] [PDF]